

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM444654

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Crescita Therapeutics Inc.		08/14/2017	Corporation: CANADA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Knight Therapeutics Inc.		
<b>Street Address:</b>	3400 De Maisonneuve W., Suite 1055		
<b>City:</b>	Montreal, Quebec		
<b>State/Country:</b>	CANADA		
<b>Postal Code:</b>	H3Z 3B8		
<b>Entity Type:</b>	Corporation: CANADA		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3413447	PLIAGLIS	
<b>Registration Number:</b>	3406582	DURAPEEL	
<b>Serial Number:</b>	86882764	CRESCITA THERAPEUTICS	
<b>Serial Number:</b>	86882855	CRESCITA THERAPEUTICS INC.	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	8324088558		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	8323388090		
<b>Email:</b>	tm@fibbelightner.com		
<b>Correspondent Name:</b>	Fibbe Lightner LLP		
<b>Address Line 1:</b>	3733-1 Westheimer, No. 1009		
<b>Address Line 4:</b>	Houston, TEXAS 77027		
<b>NAME OF SUBMITTER:</b>	A. Reagan Fibbe		
<b>SIGNATURE:</b>	/A. Reagan Fibbe/		
<b>DATE SIGNED:</b>	09/27/2017		
<b>Total Attachments: 4</b>			
source=Crescita - Confirmation of Security in IP [USA] (Execution Copy)[3]#page1.tif			
source=Crescita - Confirmation of Security in IP [USA] (Execution Copy)[3]#page2.tif			
source=Crescita - Confirmation of Security in IP [USA] (Execution Copy)[3]#page3.tif			

OP \$115.00 3413447



**CONFIRMATION OF SECURITY INTEREST IN  
TRADE MARKS, PATENTS AND RELATED INTELLECTUAL PROPERTY**

**THIS AGREEMENT** executed as of the 14<sup>th</sup> day of August, 2017

**RECITALS:**

- (a) **CRESCITA THERAPEUTICS INC.** (the “**Debtor**”), a corporation incorporated pursuant to the laws of the Province of Ontario, is the owner of the trademarks, patents and other intellectual property set forth in Exhibit "A", the registrations and applications for such trademarks, patents and intellectual property identified therein and the underlying goodwill associated with such trademarks, patents and intellectual property (collectively, the “**Intellectual Property**”); and
- (b) **KNIGHT THERAPEUTICS INC.** (the “**Secured Party**”), a corporation formed under the laws of Canada, has entered into an agreement with the Debtor, as reflected by a separate document entitled “General Security Agreement” dated as of the date hereof (as the same may be amended, modified, supplemented, extended, renewed, restated or replaced from time to time, the “**Security Agreement**”), by which the Debtor granted to the Secured Party a security interest in certain property, including the Intellectual Property, in consideration of the provision of certain credit facilities to the Debtor.


**NOW THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are acknowledged, and in accordance with the terms and obligations set forth in the Security Agreement, the Debtor hereby confirms the grant to the Secured Party of a security interest in and to the Intellectual Property.

*[Signature Page Follows]*

DATED as of the date and year first written above.

CRESCITA THERAPEUTICS INC.

By:



Name: Daniel Chicoine


Title: Executive Chairman & Interim Chief  
Executive Officer

[Signature Page to Confirmation of Security re IP - USA]

**TRADEMARK**  
**REEL: 006163 FRAME: 0580**

**EXHIBIT "A"**

**TRADE MARKS:**

TRADEMARK	COUNTRY	STATUS	TRADEMARK APPLN # (Filing Date)	REGISTRATION # (Registration Date)
CRESCITA THERAPEUTICS INC. & Design 	USA	Pending	86/882,855 (Jan 21, 2016)	
CRESCITA THERAPEUTICS	USA	Pending	86/882,764 (Jan 21, 2016)	
DURAPEEL	USA	Registered	78/515,571 (Nov 11, 2004)	3406582 (Apr 1, 2008)
PLIAGLIS	USA	Registered	78/950,628 (Aug 11, 2006)	3413447 (Apr 15, 2008)

**PATENTS:**

DESCRIPTION	COUNTRY	STATUS	PATENT APPLN # (Filing Date)	PATENT # (Grant Date)
ALPRAZOLAM	USA	Issued	12/340,246 (Dec 19, 2008)	8,927,537 (Jan 6, 2015)
DURAPEEL	USA	Issued	11/146,917 (Jun 6, 2005)	8,907,153 (Dec 9, 2014)
DURAPEEL	USA	Issued	14/533,419 (Nov 5, 2014)	9,675,562 (Jun 13, 2017) <i>Allowed Feb 27, 2017</i>
DURAPEEL	USA	Issued	11/640,139 (Dec 14, 2006)	8,741,332 (Jun 3, 2014)
DURAPEEL	USA	Issued	11/640,140 (Dec 14, 2006)	8,741,333 (Jun 3, 2014)
FLEXICAINE COMPOSITION	USA	Issued	13/006,780 (Jan 14, 2011)	9,693,976 (July 4, 2017) No PTA
FLEXICAINE COMPOSITION	USA	Pending	15/613,695 (June 5, 2017)	
FLEXICAINE COMPOSITION	USA	Pending	15/655,595 (July 20, 2017)	

DESCRIPTION	COUNTRY	STATUS	PATENT APPLN # (Filing Date)	PATENT # (Grant Date)
FLEXICAINE METHOD	USA	Issued	12/652,502 (Jan 5, 2010)	9,012,477 (Apr 21, 2015)
MMPE	USA	Issued	12/281,561 (Mar 6, 2007) [371 Jan 12, 2009]	7,795,309 (Sept 14, 2010)
MMPE	USA	Issued	12/848,792 (Aug 2, 2010)	8,343,962 (Jan 1, 2013)
MMPE	USA	Issued	13/680,623 (Nov 19, 2012)	8,513,304 (Aug 20, 2013)
MMPE	USA	Issued	13/791,460 (Mar 8, 2013)	9,308,181 (Apr 12, 2016)
MMPE	USA	Issued	14/578,812 (Dec 22, 2014)	9,642,912 (May 9, 2017)
MMPE	USA	Pending	15/491,572 (Apr 19, 2017)	
ONYCHOMYCOSIS	USA	Issued	13/525,108 (Jun 15, 2012)	9,084,754 (Jul 21, 2015)
PLIAGLIS	USA	Issued	09/407,720 (Sept 28, 1999)	6,528,086 (Mar 4, 2003)